Precision AQ’s Post

Last week's ISCT, International Society for Cell & Gene Therapy meeting was full to the brim with incredible panels and cutting-edge presentations. We attended as many as we could, here's what we thought were some of the highlights and most interesting discussions: 🔥 TILS promise for solid tumours is HOT right now ⏰ We need automation solutions EARLY - from R&D through to GMP. How do we reward early adopters through funding and regulatory channels? 🏥 Patient focus from regulatory pathways to rethinking what patient access could look like including ultra-rare and perpetual IND considerations 📈 Platform technologies were on full display this year, bringing us closer towards closed, automated and data-driven manufacturing  What would you add to the list? #ISCT24 #celltherapy #automation #bioreactors #patientaccess

BLOG – Tailoring automation for tailored medicines. The #lifesciences industry is changing from being focused on mass-produced blockbuster drugs to personalized treatments like cell and gene therapies. This change requires companies to adopt flexible, targeted automation strategies instead of a one-size-fits-all approach. Emerson life sciences expert, Christian Berg discusses how these changes demand new, adaptable solutions in manufacturing and operations. Read the full blog . #software #analytics #mes http://emr.as/3j9w50T2kWu

BLOG – Tailoring automation for tailored medicines. The #lifesciences industry is changing from being focused on mass-produced blockbuster drugs to personalized treatments like cell and gene therapies. This change requires companies to adopt flexible, targeted automation strategies instead of a one-size-fits-all approach. Emerson life sciences expert, Christian Berg discusses how these changes demand new, adaptable solutions in manufacturing and operations. Read the full blog . #software #analytics #mes http://emr.as/3j9w50T2kWu

Modular facilities, driven by the rise of cell and gene therapies, continuous manufacturing, and single-use technologies, help biomanufacturers meet clinical demands. Learn how we partnered with Siemens to create automation and digitization solutions for streamlined modular processing. Watch the video below and learn more in our white paper: https://sar.to/1xs07 #SimplifyingProgress #InThisTogether #Bioprocessing

What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications?

📢 Revolutionizing Patient Care: In-Hospital CGT Production! 🏥 Hospital-based production of cell and gene therapies can enhance patient access and reduce treatment timelines. ⏳ In-house GMP facilities ensure better quality and faster delivery compared to outsourcing. 🤝 Collaboration between hospitals for shared manufacturing could overcome high setup costs. 🔬 Overall, this centralized approach supports efficient production and patient monitoring. #BioprocessUpdates #HospitalBasedCGT #CellAndGeneTherapy #PatientAccess #GMPFacilities #HealthcareInnovation #TreatmentTimelines #CollaborativeCare #QualityHealthcare #CentralizedProduction #PatientMonitoring #GeneTherapy #CGTProduction #HealthcareCollaboration #EfficientHealthcare #FutureOfMedicine ▷ Read the full article here: 📎 https://lnkd.in/dmTZENb2

Are you ready for the next revolution in healthcare? Cell and gene therapies are poised to transform medicine as we know it. Biotech marketers and scientists face a common challenge: effectively communicating the complexities and potential of these groundbreaking therapies to stakeholders and the public. The technical nature of the field often creates barriers to understanding and engagement. Our latest blog breaks down the essentials of these innovative treatments. We explore the latest advancements, regulatory challenges, and future directions, providing you with a helpful overview of the landscape. Whether you're a marketer, scientist, or CEO, this knowledge will empower you to navigate the rapidly evolving world of cell and gene therapies with confidence. Read now: https://hubs.li/Q02KNPsG0 #BiotechMarketing #CellAndGeneTherapy #LifeScienceInnovation #Healthcare #PersonalizedMedicine

Are you finding the path to commercializing cell and gene therapies complex and uncertain? Join us as we explore this intricate landscape with our guest, Wajiha Ali. Highlights: - Uncover the hurdles of patient referrals and manufacturing regulations, amplifying the complexity of these therapies. - Explore essential commercialization strategies and infrastructure needs while balancing innovation with necessity. -Learn about navigating regulatory scrutiny and stakeholder management for safer, more accessible therapies. What do you believe are the keys to facilitating the journey from scientific breakthroughs to real-world applications? #cellculture #processdevelopment #bioprocessing #celltherapymanufacturing #cellandgenetherapy #leadbiotech

At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs: 📌 Regulatory 📌 Manufacturing and supply chain 📌 Clinical and scientific 📌 Commercial See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment. #CellAndGeneTherapy #CGT #Innovation #biopharma #EconomistImpact #curiousminds Hannah Kurth

At the Economist Impact’s Cell and Gene Therapy (CGT) 2024 Summit, experts from across the industry discussed numerous topics and challenges in the introduction of CGTs: 📌 Regulatory 📌 Manufacturing and supply chain 📌 Clinical and scientific 📌 Commercial See the attached white paper capturing important themes and takeaways from the summit, including regulatory changes and new delivery models, the need to keep conversations and practices focused on patients, and how to structure clinical trials, gather real world evidence and streamline manufacturing to help improve access to treatment. #CellAndGeneTherapy #CGT #Innovation #biopharma #EconomistImpact #curiousminds